MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria..

加利福尼亚州门洛帕克（商业新闻短讯）--生物制药公司AN2 Therapeutics，Inc.（纳斯达克：ANTX）今天宣布，该公司已获得比尔和梅琳达·盖茨基金会（Bill＆MelindaGates Foundation）第二年的研究资助，以发现用于治疗结核病（TB）和疟疾的新型含硼小分子。。

“We are appreciative of the Gates Foundation’s continued support as we advance our joint effort to discover new drugs for tuberculosis and malaria, with the goal of combating drug resistance and shortening treatment duration for these infectious diseases, which together cause nearly 2 million deaths per year worldwide,” said Eric Easom, Co-Founder, President, Chief Executive Officer and Chairman of AN2 Therapeutics.

AN2 Therapeutics联合创始人、总裁、首席执行官兼主席埃里克·伊瑟姆（EricEasom）表示：“我们感谢盖茨基金会的持续支持，因为我们推动了发现结核病和疟疾新药的共同努力，目的是对抗耐药性，缩短这些传染病的治疗时间，这些传染病每年在全球造成近200万人死亡。”。

“Our boron chemistry platform and team have a proven history of developing innovative compounds with novel mechanisms of action that address critical unmet needs in infectious diseases and other therapeutic areas. This grant highlights the potential of our boron chemistry platform and supports our commitment to address these critical gaps in global health therapeutics through non-dilutive funding.”.

“我们的硼化学平台和团队在开发创新化合物方面有着悠久的历史，这些化合物具有新颖的作用机制，可以满足传染病和其他治疗领域的关键未满足需求。这项拨款突出了我们硼化学平台的潜力，并支持我们通过非稀释性资金解决全球健康治疗中这些关键差距的承诺。”。

This grant continuation from the foundation will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform to identify new therapies for TB and malaria. Leucyl- tRNA synthetase is a validated human target in Mycobacteria and other bacteria and fungi and has the potential to address significant unmet needs in the antimicrobial space, including TB and nontuberculous Mycobacteria lung disease.

该基金会的这笔赠款将支持使用AN2专有的硼化学平台发现氨酰基-tRNA合成酶的新型抑制剂，以确定结核病和疟疾的新疗法。亮氨酰基-tRNA合成酶是分枝杆菌和其他细菌和真菌中经过验证的人类靶标，有可能解决抗菌领域的重大未满足需求，包括结核病和非结核分枝杆菌肺病。

This program builds on the scientific accomplishments and expertise of several AN2 scientists who were involved in discovering novel leucyl-tRNA synthetase inhibitors that leverage the power of boron chemistry including epetraborole, (being developed for non-tuberculosis Mycobacteria lung disease or NTM and melioidosis) tavaborole (FDA approved antifungal), and ganfeborole, which is currently in development for tuberculosis by GSK..

该项目建立在几位AN2科学家的科学成就和专业知识的基础上，这些科学家参与了发现新型亮氨酰tRNA合成酶抑制剂的研究，这些抑制剂利用了硼化学的力量，包括依哌罗尔（正在为非结核分枝杆菌肺病或NTM和类鼻疽病开发）、tavaborole（FDA批准的抗真菌药）和ganfeborole，目前正在由GSK开发用于结核病。。

About AN2 Therapeutics, Inc.

关于AN2 Therapeutics，Inc。

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

AN2 Therapeutics，Inc.是一家生物制药公司，专注于发现和开发源自其硼化学平台的新型小分子疗法。AN2正在开发一系列硼基化合物，用于恰加斯病，非结核分枝杆菌（NTM）和类鼻疽病，以及专注于传染病和肿瘤学目标的早期计划。

For more information, please visit our website at www.an2therapeutics.com..

有关更多信息，请访问我们的网站www.an2therapeutics.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the potential development of compounds, including novel inhibitors of aminoacyl-tRNA synthetases, for TB and other conditions, development of compounds through boron chemistry research, development of other compounds using our boron chemistry platform, developing compounds leveraging our experience in boron chemistry, and other statements that are not historical fact.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中表达或暗示的前瞻性声明包括但不限于以下声明：化合物的潜在开发，包括氨酰基tRNA合成酶的新型抑制剂，用于结核病和其他条件，通过硼化学研究开发化合物，使用我们的硼化学平台开发其他化合物，利用我们在硼化学方面的经验开发化合物，以及其他非历史事实的声明。

These statements are based on AN2’s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: future funding by the Gates Foundation and other sources of non-dilutive capital; timely enrollment of patients in AN2’s existing and future clinical trials; AN2’s ability to procure sufficient supply of its product candidates for its existing and future clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; AN2’s ability to obtain, maintain, or protect intellectual property rights related to its current and f.

这些声明基于AN2当前的估计、期望、计划、目标和意图，并不能保证未来的业绩，并且固有地涉及重大风险和不确定性。由于这些风险和不确定性，实际结果和事件发生的时间可能与此类前瞻性声明中的预期存在重大差异，这些风险和不确定性包括但不限于与以下相关的风险和不确定性：盖茨基金会的未来资金和其他非稀释性资本来源；及时将患者纳入AN2现有和未来的临床试验；AN2能够为其现有和未来的临床试验获得足够的候选产品供应；临床试验结果与临床前，早期临床，初步或预期结果不同的可能性；；与AN2的候选产品是否获得任何监管批准相关的重大不确定性；AN2获得、维护或保护与其当前和f相关的知识产权的能力。